share_log

SVB Leerink Maintains Outperform on bluebird bio, Raises Price Target to $72

Benzinga Real-time News ·  Mar 29, 2021 18:53

SVB Leerink analyst Mani Foroohar maintains bluebird bio (NASDAQ:BLUE) with a Outperform and raises the price target from $69 to $72.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment